Literature DB >> 35672670

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).

Piero Barbanti1,2, Gabriella Egeo3, Cinzia Aurilia3, Florindo d'Onofrio4, Maria Albanese5,6, Ilaria Cetta7, Paola Di Fiore8, Maurizio Zucco9, Massimo Filippi10, Francesco Bono11, Claudia Altamura12, Stefania Proietti13, Stefano Bonassi13,14, Fabrizio Vernieri15.   

Abstract

Entities:  

Year:  2022        PMID: 35672670      PMCID: PMC9172000          DOI: 10.1186/s10194-022-01434-8

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   8.588


× No keyword cloud information.
Correction: J Headache Pain 23, 46 (2022) https://doi.org/10.1186/s10194-022-01396-x Following the publication of the original article [1], we were notified of a mistake in the abstract: the 100% response rate in HFEM at week 12 is 5.9% (as correctly reported in figure 3) and NOT 9.9% as reported in the abstract and page 5. The original article has been corrected.
  1 in total

1.  Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).

Authors:  Piero Barbanti; Gabriella Egeo; Cinzia Aurilia; Florindo d'Onofrio; Maria Albanese; Ilaria Cetta; Paola Di Fiore; Maurizio Zucco; Massimo Filippi; Francesco Bono; Claudia Altamura; Stefania Proietti; Stefano Bonassi; Fabrizio Vernieri
Journal:  J Headache Pain       Date:  2022-04-09       Impact factor: 7.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.